drugset / Trial / NCT04145856

Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico

NCT04145856

Phase 4 Completed 55 enrolled Hospital Juarez de Mexico
RandomizedParallel-groupSingle-blindTreatment

Summary

This randomized study evaluates the usefulness of the I31 probiotic formula, alone or in combination with alverine/simethicone, against placebo, in the treatment of diarrhea-predominant or mixed irritable bowel syndrome

Timeline

Start
2018-09-03
Primary completion
2019-05-02
Completion
2019-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Alverine Small molecule 60 mg
Subject Floradapt Intensive GI Unknown 3e+09 unknown
Subject Simethicone Other / unclassified 300 mg Oral